Abstract
The pathologic diagnosis of lung cancer historically has relied primarily on morphologic features of tumors in histologic sections. With the emergence of new targeted therapies, the pathologist is called upon increasingly to provide not only accurate typing of lung cancers, but also to provide prognostic and predictive information, based on a growing number of ancillary tests, that may have significant impact on patient management. This review provides an overview of ancillary tests currently used in the pathologic diagnosis of lung cancer, with a focus on immunohistochemistry and molecular diagnostics. © Copyright 2012 William Dubinski et al.
Cite
CITATION STYLE
Dubinski, W., Leighl, N. B., Tsao, M. S., & Hwang, D. M. (2012). Ancillary testing in lung cancer diagnosis. Pulmonary Medicine. https://doi.org/10.1155/2012/249082
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.